Antitrust Antitrust

South Korea's Daewoong Pharmaceutical sanctioned for filing fake patent infringement litigation

By Jenny Lee
  • 03 Mar 2021 01:16
  • 03 Mar 2021 01:16
Daewoong Pharmaceutical was slapped with sanctions today by the South Korean antitrust regulator for abusing the country's patent infringement litigation system.
In a statement released today, the Korea Fair Trade Commission, or KFTC, imposed a corrective order and a fine of 2.27 billion won ($2 million) on Daewoong for unreasonably

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Jenny Lee

Correspondent


Jenny joined MLex’s Seoul bureau in 2021 as a correspondent focusing on competition law and data privacy and security. Jenny received a Master’s degree from Northwestern University’s renowned Medill School of Journalism and worked for a number of news organizations in the US, including the Associated Press Television News, McClatchy and Voice of America, where she worked for almost three years in Washington DC. She returned to her native South Korea in 2019 as a reporter for Wired Korea.

Discover MLex

Stay on top of global regulatory developments

Latest News